Acquisition

Sigma Healthcare Pursues Potential Boots Acquisition Deal

Yuvraj — Thu, 11 Jun 2026 13:13:11 +0000

Australia’s Sigma Healthcare has confirmed that it is participating in discussions regarding a possible acquisition of Boots, the UK health and beauty retailer, in a transaction reportedly valued at up to $10 billion. The company acknowledged its interest after reports emerged that it was among several parties considering a bid for the British chain. In […]

The post Sigma Healthcare Pursues Potential Boots Acquisition Deal first appeared on World Pharma Today.

Incyte Expands Haematology Portfolio with Vega Acquisition

Yuvraj — Wed, 10 Jun 2026 12:29:31 +0000

Incyte has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction valued at up to $2bn, reinforcing its presence in haematology with the addition of a late-stage treatment candidate for bleeding disorders. Under the terms of the deal, Incyte will pay $1.25bn upfront and could provide up to $750m in additional […]

The post Incyte Expands Haematology Portfolio with Vega Acquisition first appeared on World Pharma Today.

GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition

Yuvraj — Wed, 10 Jun 2026 12:18:54 +0000

GSK has agreed to acquire Nuvalent in a transaction valued at $10.6 billion, positioning the UK-based pharmaceutical company for its largest acquisition in more than a decade and adding two late-stage lung cancer treatments to its portfolio. Through a tender offer, GSK will seek to purchase Nuvalent shares at $124 each and plans to finance […]

The post GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition first appeared on World Pharma Today.

Firefly Bio Acquisition Strengthens J&J Cancer Pipeline

Yuvraj — Wed, 10 Jun 2026 12:12:40 +0000

Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Firefly Bio for $1bn in cash, a move aimed at expanding its oncology research portfolio through the addition of Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) technology. The Firefly Bio acquisition is focused on advancing new treatment approaches for solid tumours associated with […]

The post Firefly Bio Acquisition Strengthens J&J Cancer Pipeline first appeared on World Pharma Today.

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position

Yuvraj — Tue, 09 Jun 2026 07:58:55 +0000

GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8 billion. The deal will make Ayumi a wholly owned subsidiary of GNI Group and significantly expands […]

The post GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position first appeared on World Pharma Today.

CordenPharma Seals AmbioPharm Deal to Expand Global Network

Yuvraj — Sat, 30 May 2026 08:25:37 +0000

CordenPharma, a global contract development and manufacturing organization specializing in complex drug modalities, has officially entered into an agreement to acquire AmbioPharm. The AmbioPharm Deal strengthens the company’s manufacturing presence in the United States while adding newly integrated production capabilities in Shanghai, China. The move allows CordenPharma to comprehensively support the growing global demand for […]

The post CordenPharma Seals AmbioPharm Deal to Expand Global Network first appeared on World Pharma Today.

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Yuvraj — Tue, 12 May 2026 08:55:49 +0000

Angelini Pharma has finalized a definitive agreement to acquire Catalyst Pharmaceuticals for an equity value of approximately €3.5bn ($4.1bn). This move marks a strategic entry into the US market for the company, further consolidating its operational focus on brain health and the treatment of complex conditions. The transaction, which has received unanimous approval from the […]

The post Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition first appeared on World Pharma Today.

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Yuvraj — Thu, 30 Apr 2026 09:45:39 +0000

Teva Pharmaceuticals has entered into a definitive agreement to acquire Emalex Biosciences, strengthening its neuroscience pipeline through the addition of ecopipam, a late-stage investigational treatment for pediatric Tourette syndrome. The move reinforces the company’s strategic shift toward innovation-led expansion, with ecopipam positioned as a registration-ready, first-in-class selective dopamine D1 receptor antagonist. The asset has already […]

The post Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal first appeared on World Pharma Today.

Sun Pharma Organon Buyout Marks Largest Biopharma Deal 2026

Yuvraj — Wed, 29 Apr 2026 11:48:50 +0000

Sun Pharmaceutical Industries has agreed to acquire Organon in a transaction valued at $11.75 billion, creating what the company described as the largest Biopharma Deal recorded in 2026. The agreement brings together two businesses that each generated $6.2 billion in revenue in 2025, effectively doubling Sun Pharma’s scale and strengthening its global position. Already India’s […]

The post Sun Pharma Organon Buyout Marks Largest Biopharma Deal 2026 first appeared on World Pharma Today.

Eli Lilly Kelonia Acquisition Advances in $2B Deal Talks

Yuvraj — Tue, 21 Apr 2026 05:47:56 +0000

Eli Lilly and Company is in advanced discussions to acquire Kelonia Therapeutics for more than $2 billion, according to a report by The Wall Street Journal. The report, citing people familiar with the matter, indicates that a deal could be finalized as early as Monday and may include additional payments tied to the achievement of […]

The post Eli Lilly Kelonia Acquisition Advances in $2B Deal Talks first appeared on World Pharma Today.